Please assess the completion status of the following clinical trial:

Trial Title: Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure. AREA IN-CHF Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Established diagnosis of congestive heart failure in NYHA class II~* Left ventricular ejection fraction \<= 45% measured within 6 months from enrolment~* Stable standard heart failure therapy (if patients are on beta blocker drugs, treatment must have been started at least three months before enrolment)~* Informed consent (obtained prior of any study procedures)~Exclusion Criteria:~* Age \<18 and \>80~* Serum creatinine level \> 2.5 mg per deciliter~* Serum potassium level \> 5.0 mmol per liter~* Valvular heart disease amenable to surgical treatment~* Congenital heart disease~* Unstable angina and/or acute myocardial infarction and/or coronary revascularization procedure within three months before enrolment~* Intravenous therapy with inotropic drugs within three months before enrolment~* History of resuscitated ventricular fibrillation or tachycardia, unless these occurred within 24 hours of an acute myocardial infarction or the subject has an implanted an automatic cardioverter defibrillator~* Chronic active hepatitis or cirrhosis~* Malignant neoplasm or any life threatening non cardiac disease~* History of hypersensitivity to study drug~* Pregnancy or lactating or childbearing age women who are not protected by an accepted method of contraception~* History of drug or alcohol abuse~* Legal incapacity and/or other circumstances rending the patient unable to understand the nature, scope and possible consequences of the study.~* Evidence of uncooperative attitude~* Any condition other than heart failure that does not permit an optimal participation to the trial~* Participation to other RCTs during the last 3 months~* Treatment with: Lithium salts, Potassium sparing diuretics, oral positive inotropic drugs or any investigational drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).